TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03913429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration
Description: Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary nerve blockade
Description: Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF.
Study: NCT02908191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Study: NCT03169335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
Study: NCT02908191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Study: NCT03169335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
Study: NCT04469972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
Study: NCT02908191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABI-H0731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Used to treat adults with chronic hepatitis B virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Used to treat adults with chronic hepatitis B virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Used to treat adults with chronic hepatitis B virus who show signs of liver damage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide
Description: Used to treat adults with chronic hepatitis B virus
Study: NCT03414099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketum
Description: Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink matched for taste and appereance
Study: NCT04190251

Intervention type: OTHER
Group type: OTHER
Intervention: Inteprofessional medication adherence support program (IMAP)
Description: In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.

Intervention type: OTHER
Group type: OTHER
Intervention: Inteprofessional medication adherence support program (IMAP)
Description: In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
Study: NCT03998696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 40 mg/m2
Description: Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2
Description: Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
Study: NCT02775409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous placement
Description: The tissue expander will be placed above the muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submuscular placement
Description: The tissue expander will be placed below the muscle
Study: NCT02424357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5%povidone iodine ophthalmic solution
Description: one drop of 5% povidone iodine instilled into the conjunctival fornix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine post-operative ophthalmic ointment
Description: patient received a routine antibiotic/steroid ointment to operated eye at surgery completion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine post-operative ophthalmic ointment
Description: patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
Study: NCT01977924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one month polyphenols supplementation (600mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (microcrystalline cellulose)
Study: NCT02259166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHFP+
Description: Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
Study: NCT02602470

Intervention type: DRUG
Intervention: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
Description: Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing

Intervention type: DRUG
Intervention: Azelaic Acid Cream
Description: Azelaic Acid Cream 20%

Intervention type: DRUG
Intervention: Metronidazole gel
Description: Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser

Intervention type: DRUG
Intervention: Metronidazole cream
Description: Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser

Intervention type: DRUG
Intervention: Metronidazole Emulsion
Description: Metronidazole Emulsion 0.75%

Intervention type: DRUG
Intervention: Metronidazole Lotion
Description: Metronidazole Lotion 0,75%

Intervention type: DRUG
Intervention: Brimonidine Tartrate Gel
Description: Brimonidine Tartrate Gel 0.33%
Study: NCT03250611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipital Condyle Screw
Description: Occipito-Cervical Screw-Rod Fixation Technique
Study: NCT01351324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Absence or presence of fish oil
Description: Oral dose of saturated fat with or without fish oil and a heparin infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Absence or presence of fish oil
Description: Oral dose of saturated fat with or without fish oil and a heparin infusion
Study: NCT00000439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium valproate
Description: subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
Study: NCT03130556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
Study: NCT01302392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).
Study: NCT03130556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat, High Calorie Meal
Description: A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
Study: NCT03914417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% Cream
Description: Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
Study: NCT02021669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Description: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Study: NCT01597336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator abscess flush
Description: Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline flush of abscess
Description: Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
Study: NCT02956694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional e-learning program on shared decision making
Description: Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
Study: NCT00154297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (RAD001)
Study: NCT04348799

Intervention type: OTHER
Intervention: BPD
Description: It is a observation research.we didn't intervene anything.
Study: NCT02581826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silodosin
Description: α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No column specified.
Study: NCT04271254

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
Study: NCT02147756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2RE
Description: Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Study: NCT03395431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fingerprick autologuos blood (FAB)
Description: Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
Study: NCT03973242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual focus with narrow band imaging
Description: dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual focus with narrow band imaging
Description: dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
Study: NCT03879889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
Study: NCT04514601

Intervention type: OTHER
Intervention: Standard Operating Protocol
Description: This was a written protocol on how the handover process should be conducted.
Study: NCT03689764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study: NCT03811652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Study: NCT04339816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: orally or into nasogastric tube for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: orally or into nasogastric tube for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: orally or into nasogastric tube for 5 days
Study: NCT04310761

Intervention type: PROCEDURE
Intervention: one single blastocyst transfer, both fresh and warmed
Description: Ultrasound guided transvaginal embryo transfer.
Study: NCT04339816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally or into nasogastric tube for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: orally or into nasogastric tube for 5 days
Study: NCT01242592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tuberculosis Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Tuberculosis Treatment
Study: NCT00179413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG -Intron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.6mg twice a day
Study: NCT03764644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined ABMT and CBT
Description: ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined Sham ABMT and CBT
Description: ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
Study: NCT02609061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
Study: NCT03309683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Quick Clip Pro - Single Use Repositionable Clips
Description: A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
Study: NCT01701661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: stripping of main trunk or if previously removed, removal or ligating the refluating trunk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: Compression stockings class II
Study: NCT02171598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran low dose
Study: NCT00694967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McDonald cerclage placement
Description: Transcervical McDonald cerclage placement